Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
shivering; This non-serious case was reported by a consumer via call center representative and described the occurrence of shivering in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Concurrent medical conditions included depression and suicidal ideation. Family history included shingles (Patient father had Shingles in the past). In FEB-2022, the patient received the 1st dose of Shingrix. In FEB-2022, less than a day after receiving Shingrix, the patient experienced shivering (Verbatim: shivering). The outcome of the shivering was resolved (duration 1 day). It was unknown if the reporter considered the shivering to be related to Shingrix. It was unknown if the company considered the shivering to be related to Shingrix. Linked case(s) involving the same patient: US2024137579 Additional Information: GSK Receipt Date: 23-APR-2025 The patient added that she also experienced shivering with dose one Shingrix. The shivering started within 24 hours of receiving vaccine and resolved in a day.; Sender's Comments: US-GSK-US2024137579:same patient
Depression; Suicidal ideation
Medical History/Concurrent Conditions: Shingles (Patient father had Shingles in the past)